Pathogenesis of cardiovascular diseases: effects of mitochondrial CF6 on endothelial cell function

Area of Science:

• Biochemistry
• Cardiovascular Biology
• Molecular Medicine

Background:

• Cardiovascular disease (CVD) is a leading cause of death globally, requiring effective risk reduction strategies.
• Mitochondrial coupling factor 6 (CF6) is identified as a novel proatherogenic peptide and a significant risk factor for endothelial dysfunction.
• CF6 levels are elevated in patients with essential hypertension, atherosclerotic cardiovascular disease (ASCVD), stroke, and preeclampsia.

Purpose of the Study:

• To provide a comprehensive review of CF6's role in cardiovascular disease (CVD).
• To elucidate the mechanistic insights into CF6's function, intracellular signaling, and regulatory mechanisms in vascular endothelial cells.

Main Methods:

• Literature review of studies investigating the relationship between CF6 and CVD.
• Analysis of CF6's impact on endothelial cell function, including nitric oxide (NO) and prostacyclin generation.
• Exploration of signaling pathways involved in CF6-mediated endothelial dysfunction, such as NF-κB and C-src Ca2+ pathways.

Main Results:

• CF6 acts as a vasoactive and proatherogenic peptide, contributing to CVD development.
• CF6 induces intracellular acidosis, inhibits NO and prostacyclin, increases blood pressure, and promotes proatherogenic molecules.
• CF6 disrupts the balance of endothelium-dependent factors (NO, prostacyclin, ADMA), leading to vasoconstriction, vascular remodeling, thrombosis, and insulin resistance.

Conclusions:

• CF6 plays a critical role in the pathogenesis of cardiovascular disease.
• Understanding CF6's mechanisms in vascular endothelial cells is crucial for developing novel CVD therapies.
• Targeting CF6 or its related pathways may offer a new therapeutic avenue for cardiovascular risk reduction.